# ImmunityBio, Inc. clinical trials: 83 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 83 trials with ImmunityBio, Inc. as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ImmunityBio, Inc.: 83 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/immunitybio-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 83
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 83, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 25, 2026 | NCT07783789 | NAI Plus Standard of Care Compared To SOC Alone Plus Standard of Care in Critically Ill Adults With Sepsis | ImmunityBio, Inc. | Phase 2 | Not yet recruiting | Sepsis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783789) |
| June 4, 2026 | NCT07628062 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared... | ImmunityBio, Inc. | Phase 2 | Not yet recruiting | HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628062) |
| May 11, 2026 | NCT07578558 | NAI for Sepsis With Persistent Lymphopenia | ImmunityBio, Inc. | Phase 2 | Withdrawn | Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578558) |
| April 29, 2026 | NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | ImmunityBio, Inc. | Phase 1 | Terminated | B-ALL, Leukemia | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556757) |
| April 27, 2026 | NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | ImmunityBio, Inc. | Phase 3 | Withdrawn | NMIBC | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551544) |
| April 13, 2026 | NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | ImmunityBio, Inc. | Phase 3 | Withdrawn | NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524257) |
| March 25, 2026 | NCT07492888 | Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | ImmunityBio, Inc. | Phase 2 | Withdrawn | Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492888) |
| March 25, 2026 | NCT07492875 | Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia | ImmunityBio, Inc. | Phase 3 | Withdrawn | Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia, Immunoparalysis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492875) |
| March 23, 2026 | NCT07488884 | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With... | ImmunityBio, Inc. | Phase 1 | Withdrawn | Pancreatic Cancer Resectable, Pancreatic Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488884) |
| March 17, 2026 | NCT07477366 | Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | ImmunityBio, Inc. | Phase 2 | Not yet recruiting | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477366) |
| October 16, 2025 | NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | ImmunityBio, Inc. | Phase 1 | Not yet recruiting | Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217496) |
| August 15, 2025 | NCT07125872 | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | ImmunityBio, Inc. | Phase 2 | Recruiting | Relapsed B-Cell Non Hodgkin Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07125872) |
| August 14, 2025 | NCT07123727 | A Study to Examine Anktiva for the Treatment of COVID-19. | ImmunityBio, Inc. | Phase 2 | Recruiting | Long COVID, Long COVID Syndrome, Long Covid 19 | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07123727) |
| August 6, 2025 | NCT07108036 | A Study to Assess Anktiva in Patients With Long Covid-19. | ImmunityBio, Inc. | Phase 2 | Recruiting | Long COVID | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108036) |
| May 4, 2025 | NCT06956547 | Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of... | ImmunityBio, Inc. | Not applicable | Available | Lymphopenia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956547) |
| February 17, 2025 | NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | ImmunityBio, Inc. | Phase 2 | Not yet recruiting | Non-muscle Invasive Bladder Cancer (NMIBC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06829823) |
| February 5, 2025 | NCT06810141 | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer | ImmunityBio, Inc. | Not applicable | Available | NMIBC | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810141) |
| January 30, 2025 | NCT06800963 | ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | ImmunityBio, Inc. | Phase 1/2 | Recruiting | NMIBC | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06800963) |
| January 9, 2025 | NCT06765954 | Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. | ImmunityBio, Inc. | Phase 2 | Withdrawn | High-risk Prostate Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06765954) |
| January 9, 2025 | NCT06765902 | Immunotherapy Before and After Surgery | ImmunityBio, Inc. | Phase 2 | Withdrawn | High-risk Prostate Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06765902) |
| December 20, 2024 | NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in... | ImmunityBio, Inc. | Phase 3 | Recruiting | NSCLC Stage IV | 507 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06745908) |
| November 29, 2024 | NCT06710288 | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With... | ImmunityBio, Inc. | Phase 2 | Recruiting | Platinum-resistant Ovarian Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710288) |
| March 28, 2024 | NCT06334991 | Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | ImmunityBio, Inc. | Phase 1 | Active not recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06334991) |
| September 29, 2023 | NCT06061809 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | ImmunityBio, Inc. | Phase 2 | Active not recruiting | Glioblastoma | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06061809) |
| September 18, 2023 | NCT06040918 | Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis | ImmunityBio, Inc. | Phase 1 | Completed | Healthy Subjects | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06040918) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 1/2 | 26 |
| Phase 2 | 25 |
| Phase 2/3 | 2 |
| Phase 3 | 6 |
| Not applicable | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Withdrawn | 25 |
| Completed | 18 |
| Terminated | 17 |
| Active not recruiting | 9 |
| Recruiting | 7 |
| Not yet recruiting | 5 |
| Available | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 9 |
| Pancreatic Neoplasms | 8 |
| Non-Muscle Invasive Bladder Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Neoplasm Metastasis | 6 |
| Carcinoma, Merkel Cell | 4 |
| Carcinoma, Transitional Cell | 4 |
| Sepsis | 4 |
| Lymphopenia | 4 |
| Sarcoma | 4 |
| Critical Illness | 3 |
| Colorectal Neoplasms | 3 |
| Lymphoma, B-Cell | 3 |
| Urinary Bladder Neoplasms | 3 |
| Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Prostatic Neoplasms | 2 |
| Small Cell Lung Carcinoma | 2 |
| Community-Acquired Pneumonia | 2 |
| Respiratory Distress Syndrome | 2 |
| Post-Acute COVID-19 Syndrome | 2 |
| Melanoma | 2 |
| Glioblastoma | 2 |
| Recurrence | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [Cigar bars in the United States](https://specstream.ai/data/businesses/cigar-bars/united-states)
- [Kitchen remodelers in the United States](https://specstream.ai/data/businesses/kitchen-remodelers/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [IT service companies in the United States](https://specstream.ai/data/businesses/it-service-companies/united-states)
